DSMB confirms higher doses of temelimab in ProTEct-MS Phase 2 study are well tolerated
▪ Study conducted at Karolinska Institutet’s Academic Specialist Center (ASC) in Stockholm
▪ Phase 2 top-line results on track to be reported in Q1 2022
Geneva, Switzerland, March 2, 2021 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that the independent Drug Safety Monitoring Board (DSMB) has concluded the Phase 2 trial of temelimab in MS patients should continue as planned without modification. This follows a pre-determined review of the first 8 patients treated with temelimab for 2 months at doses of 18, 36 and 54 mg/kg. The study, called ProTEct-MS, is being conducted at the Karolinska Institutet’s Academic Specialist Center (ASC), in Stockholm (Sweden).
For more information http://www.geneuro.com/data/news/GeNeuro-MS-Study-DSMB-Approval-ENG.pdf
